Predicting Disabling Crohn’s Disease Using Magnetic Resonance Enterography at Diagnosis
Overview
The METRIC-EF study developed a multivariable predictive model using Magnetic Resonance Enterography (MRE) features at diagnosis to forecast disabling Crohn’s disease within five years. This multicenter cohort study demonstrated that MRE can quantify bowel damage and inflammation, aiding early identification of patients at risk for progressive disease.
Background
Crohn’s disease (CD) often leads to significant morbidity due to complications such as strictures, fistulae, and abscesses. Disabling disease, characterized by events like hospitalizations, steroid dependency, and surgery, lacks a universal definition but indicates a progressive course. Early aggressive treatment with biologics and immunomodulators may reduce progression but carries risks and costs, highlighting the need for accurate prognostic tools. Magnetic Resonance Enterography (MRE) is a first-line imaging modality that can assess both bowel damage and inflammation simultaneously, yet its prognostic utility in newly diagnosed CD patients has been underexplored.
Data Highlights
The METRIC-EF trial included adult patients with newly diagnosed Crohn’s disease from nine UK NHS hospitals, followed for a minimum of 4 years (mean 5.5 years). MRE indices calculated included the Magnetic Resonance Enterography Global Score (MEGS), simplified magnetic resonance index of activity (sMARIA), and the Lémann index (LI). Disabling disease was defined by a modified Beaugerie et al. criteria excluding early events within 90 days of diagnosis and use of disease-modifying therapy. Consensus panels reviewed clinical and imaging data to classify outcomes and collect predictor variables.
Key Findings
MRE features at diagnosis can quantify bowel damage and inflammatory activity relevant to disease progression.
The study defined disabling Crohn’s disease as events occurring more than 90 days post-diagnosis, including steroid dependency, hospitalizations, chronic disabling symptoms, immunosuppressive therapy, and surgery.
MRE indices such as MEGS, sMARIA, and Lémann index were used to assess disease severity and damage.
The predictive model incorporated clinical and imaging data from a multicenter cohort with extended follow-up (mean 5.5 years).
The study excluded patients with disabling disease at diagnosis or within 90 days to focus on forecasting future disabling disease.
Clinical Implications
Incorporating MRE features at diagnosis into prognostic models may enable clinicians to identify patients at high risk for disabling Crohn’s disease early in their disease course. This stratification can guide personalized treatment decisions, potentially optimizing the timing of aggressive therapies while minimizing unnecessary exposure in lower-risk patients. The use of standardized MRE scoring systems enhances reproducibility and clinical applicability.
Conclusion
The METRIC-EF study supports the utility of Magnetic Resonance Enterography at diagnosis to predict disabling Crohn’s disease within five years, offering a valuable tool for early risk stratification and management planning in newly diagnosed patients.
References
Beaugerie et al. 2006 -- Definition of disabling Crohn’s disease
METRIC Study Group 2019 -- Magnetic Resonance Enterography or Ultrasound in Crohn’s Disease
British Society of Gastrointestinal and Abdominal Radiology (BSGAR) -- MRE scoring systems
by Stuart A. Taylor, Shankar Kumar, Thomas Parry, Sue Mallett, Simon Travis, Tim Raine, Caroline Clarke, Jing Yi Weng, Gauraang Bhatnagar, Stuart Bloom, Peter John Hamlin, Ailsa Hart, Roser Vega, Maira Hameed, Anisha Bhagwanani, Rebecca Greenhalgh, Emma Helbren, James Stephenson, Ian Zealley, Vivienne Eze, Jamie Franklin, Alison Corr, Arun Gupta, Damian Tolan, William Hogg, Antony Higginson, Mohamed Ahmed, Louise Lee, Richard Pollok, Jaymin Patel, Samantha Baillie, Steve Halligan, Andrew Plumb
